Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln
Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln is drawing significant interest across the industry.
Hong Kong-listed Sino Biopharmaceutical said on Wednesday its unit has ?signed an exclusive global licensing deal ?with French drugmaker Sanofi worth up to $1.53 billion, giving the European pharma giant rights ?to a blood cancer drug ?that won Chinese regulatory approval last ?month.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Erebor Secures First New US Bank Charter of Trump’s Second Term
- Deep-sea fish break the mold with novel visual system
- Hacker Exploits Anthropic Claude to Steal 150GB of Mexican Data
- San Francisco's Transamerica building is being sold
Source: Original →